Since more than 90% of patients with HNSCC have overexpressed EGFR or random mutations, targeting this receptor is crucial for impeding cancer progression (Kalyankrishna and Grandis, 2006; Nair et al., 2022). The gene discussed is EGFR; the disease is cancer.